Stock CVKD CADRENAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cadrenal Therapeutics, Inc.

Equities

CVKD

US1276361086

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
0.46 USD -5.23% Intraday chart for Cadrenal Therapeutics, Inc. -6.22% -37.83%
May. 09 Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 09 Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
PR
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
PR
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
PR
CADRENAL THERAPEUTICS TO PARTICIPATE AT TECHNOLOGY AND HEART FAILURE THERAPEUTICS CONFERENCE
AQ
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
PR
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
PR
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
PR
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference
PR
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target
PR
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization
PR
Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023
PR
Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update
PR
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference
PR
CADRENAL THERAPEUTICS HIGHLIGHTS ADDITIONAL NEED FOR A NEW VITAMIN K ANTAGONIST FOLLOWING UPDATES FROM THE RECENT EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS
AQ
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress
PR
CADRENAL THERAPEUTICS EXPANDS EVALUATION OF TECARFARIN FOR PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
AQ
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
PR
Cadrenal Therapeutics : Shareholder Director Nominations - Form 8-K
PU
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update
PR
Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CVKD Stock
  4. News Cadrenal Therapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW